Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
14
×
Tags
boston blog main
14
×
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
14
×
fda
clinical trials
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
national
drugs
cancer
pfizer
akcea therapeutics
alnylam pharmaceuticals
eli lilly
inotersen
patisiran
tafamidis
amgen
boston
What
fda
14
×
drug
approved
bio
medicine
roundup
alnylam
drugs
new
patients
won
approval
medicines
news
time
ago
cancer
class
companies
decades
developed
disease
friday
gene
genetic
gets
make
migraine
oks
oral
rna
rnai
therapy
uses
year
activity
afternoon
agency
ahead
aimmune
Language
unset
Current search:
photo
×
fda
×
" boston blog main "
×
" san diego top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines